Regend Therapeutics
Clinical trials sponsored by Regend Therapeutics, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Stem cell trial aims to regrow lungs in COPD patients Results expected Oct 2026 (estimated)
- Stem cells injected for lung scarring: early trial begins Results expected Feb 2027 (estimated)
-
Can a Patient's own airway stem cells repair damaged lungs in COPD?
Disease control Not yet recruitingResearchers are testing REGEND001, a therapy made from a patient's own airway basal stem cells, to see if it can improve lung function in people with chronic obstructive pulmonary disease (COPD) and emphysema. The trial enrolls adults aged 40 to 75 with moderate to severe COPD. P…
Phase 3 • Sponsor: Regend Therapeutics • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Stem cells injected for lung scarring: early trial begins
Disease control Not yet recruitingThis early-phase trial will test a stem cell product called REGEND007 in 12 people with idiopathic pulmonary fibrosis (IPF), a disease that scars the lungs and makes breathing hard. The stem cells are given through an IV, and the main goal is to check safety and find the right do…
Early phase 1 • Sponsor: Regend Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC